A convergent trend is emerging that reframes Alzheimer's disease (AD) not merely as a neuronal amyloid/tau disorder but as a failure of a coordinated, multi-cellular "blood-brain barrier senescence unit"—comprising microglia, astrocytes, pericytes, and T cells—whose aging and cross-talk actively drive pathology. Single-nucleus RNA sequencing across 75 human brain samples has identified this unit and pinpointed a specific molecular circuit, the SPP1-CD44 axis, as its central signaling mechanism: senescent microglia upregulate SPP1, which binds CD44 overexpressed on senescent astrocytes, establishing a self-sustaining inflammatory loop that perpetuates AD pathology. This shifts mechanistic emphasis from static protein aggregation toward dynamic, cell-intrinsic senescence programs and their paracrine amplification, with SPP1 validated as a disease-correlated hub gene both computationally and in patient cerebrospinal fluid proteomics—lending translational credibility to this axis as a biomarker and drug target rather than a purely descriptive finding.
Therapeutically, this trend bifurcates into two complementary strategies converging on the same node: senolytic interventions aimed at eliminating or reprogramming senescent microglia/astrocytes, and anti-inflammatory interventions designed to disrupt SPP1-CD44 signaling and break the inflammatory loop before it sustains further senescence spread across the BBB unit. This positions SPP1 as a dual-purpose target—both a biomarker for staging senescence burden and a druggable node for intervention—bridging cellular senescence biology with neuroinflammation research in AD.
Parallel to the senescence-inflammation axis, astrocyte-targeted gene therapy is advancing as a separate but complementary trajectory: astrocytic expression of the protective APOE3-Christchurch variant reduces amyloid-β pathology in 5xFAD transgenic mice, demonstrating that astrocytes are not only pathological participants (via CD44-mediated senescence signaling) but also viable therapeutic delivery vehicles. Together, these threads point to an integrated future treatment landscape in which cell-type-specific interventions—senolytics/anti-inflammatories to quell the SPP1-CD44 loop, and engineered protective variants delivered via astrocytes—are combined to simultaneously target amyloid accumulation and the senescent-inflammatory microenvironment that sustains it, with mouse models (5xFAD) and human multi-omic validation (snRNA-seq, CSF proteomics) providing the preclinical-to-clinical translational pipeline.